- Home
- FOXF vs AKRO Comparison
FOXF vs AKRO Comparison
Compare FOXF & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOXF
- AKRO
- Stock Information
- Founded
- FOXF 2007
- AKRO 2017
- Country
- FOXF United States
- AKRO United States
- Employees
- FOXF N/A
- AKRO N/A
- Industry
- FOXF Motor Vehicles
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- FOXF Consumer Discretionary
- AKRO Health Care
- Exchange
- FOXF Nasdaq
- AKRO Nasdaq
- Market Cap
- FOXF 1.6B
- AKRO 2.1B
- IPO Year
- FOXF N/A
- AKRO 2019
- Fundamental
- Price
- FOXF $37.00
- AKRO $31.59
- Analyst Decision
- FOXF Hold
- AKRO Strong Buy
- Analyst Count
- FOXF 6
- AKRO 7
- Target Price
- FOXF $46.17
- AKRO $43.20
- AVG Volume (30 Days)
- FOXF 293.5K
- AKRO 441.5K
- Earning Date
- FOXF 10-31-2024
- AKRO 11-11-2024
- Dividend Yield
- FOXF N/A
- AKRO N/A
- EPS Growth
- FOXF N/A
- AKRO N/A
- EPS
- FOXF 0.98
- AKRO N/A
- Revenue
- FOXF $1,345,575,000.00
- AKRO N/A
- Revenue This Year
- FOXF N/A
- AKRO N/A
- Revenue Next Year
- FOXF $10.04
- AKRO N/A
- P/E Ratio
- FOXF $37.96
- AKRO N/A
- Revenue Growth
- FOXF N/A
- AKRO N/A
- 52 Week Low
- FOXF $34.56
- AKRO $11.36
- 52 Week High
- FOXF $86.14
- AKRO $37.00
- Technical
- Relative Strength Index (RSI)
- FOXF 40.65
- AKRO 66.34
- Support Level
- FOXF $36.65
- AKRO $29.34
- Resistance Level
- FOXF $38.36
- AKRO $32.15
- Average True Range (ATR)
- FOXF 1.35
- AKRO 1.26
- MACD
- FOXF -0.21
- AKRO 0.10
- Stochastic Oscillator
- FOXF 20.19
- AKRO 99.74
About FOXF Fox Factory Holding Corp.
Fox Factory Holding Corp is a designer, manufacturer, and marketer of performance-defining products and systems used predominantly on bikes, Side-by-Sides, on-road vehicles with and without off-road capabilities, off-road vehicles and trucks, ATVs, snowmobiles, specialty vehicles and applications, motorcycles, and commercial trucks. Its business operates under the FOX, FOX RACING SHOX, and RACE FACE brands. Geographically, it derives a majority of revenue from North America and also has a presence in Asia, Europe, and the Rest of the World.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.